15 research outputs found
Reconstruction of a three-dimensional, transonic rotor flow field from holographic interferogram data
Holographic interferometry and computerized aided tomography (CAT) are used to determine the transonic velocity field of a model rotor blade in hover. A pulsed ruby laser recorded 40 interferograms with a 2 ft dia view field near the model rotor blade tip operating at a tip Mach number of 0.90. After digitizing the interferograms and extracting the fringe order functions, the data are transferred to a CAT code. The CAT code then calculates the perturbation velocity in several planes above the blade surface. The values from the holography-CAT method compare favorably with previously obtained numerical computations in most locations near the blade tip. The results demonstrate the technique's potential for three dimensional transonic rotor flow studies
Transonic rotor flow-measurement technique using holographic interferometry
Holographic interferometry is used to record interferograms of the flow near a hovering transonic rotor blade. A pulsed ruby laser recorded 40 interferograms with a 2 ft dia. view field near the model rotor blade tip operating at a tip Mach number of 0.90. The experimental procedure is presented and example interferograms recorded in the rotor's tip path plane. In addition, a method currently being pursued to obtain quantitative flow information using computer assisted tomography (CAT) with the holographic interferogram data, is outlined
Comparisons of morphometric measurements and serum insulin-like growth factor concentration in healthy cats and cats with hypertrophic cardiomyopathy
Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B‐type natriuretic peptide levels
Recommended from our members
Elevated Uric Acid Levels Predict Allograft Vasculopathy in Cardiac Transplant Recipients
Cardiac allograft vasculopathy (CAV) poses the greatest threat to the long-term survival of cardiac transplant recipients, and these individuals often exhibit elevated levels of uric acid (UA), a stimulator of T cells. We hypothesized that hyperuricemia is associated with CAV in cardiac transplant recipients.
UA levels were measured in cardiac transplant recipients between January 2003 and January 2005. Surveillance cardiac catheterizations performed 3 months to 1 year after UA measurement were reviewed. The relationship between UA and CAV was adjusted for possible confounders with propensity scores and confirmed with goodness-of-fit tests.
The 105 patients included in this study were a median 63.3 months post-transplant and their left heart catheterizations were performed a median 5.6 months after UA measurement. Focal stenosis was evident in 25 angiograms and 31 showed distal pruning of the coronary arteries. Compared with the lowest quartile of UA, the highest quartile had an increased risk of CAV: odds ratio (OR) 6.11 (95% CI 1.47 to 25.5;
p = 0.013) for focal stenosis and OR 4.60 (95% CI 1.34 to 15.8;
p = 0.015) for distal pruning. After adjustment, this relationship persisted for both focal stenosis (OR 5.53, 95% confidence interval [CI] 1.29 to 23.7;
p = 0.021) and distal pruning (OR 4.21, 95% CI 1.15 to 15.4;
p = 0.029).
Elevated UA confers an increased risk of CAV. This association may be causal, with pathophysiologic implications for the role of hyperuricemia in allograft failure and, if substantiated, could have clinical implications for the use of xanthine oxidase inhibitors in cardiac transplant recipients
Reconstruction of a Three-Dimensional, Transonic Rotor Flowfield from Holographic Interferograms
Elements of Successful Universal Student Transit Pass Programs from Planning to Implementation: A Benchmark Study
Symptomology following mRNA vaccination against SARS-CoV-2
Despite demonstrated efficacy of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19), widespread hesitancy to vaccination persists. Improved knowledge regarding frequency, severity, and duration of vaccine-associated symptoms may help reduce hesitancy. In this prospective observational study, we studied 1032 healthcare workers who received both doses of the Pfizer-BioNTech SARS-CoV-2 mRNA vaccine and completed post-vaccine symptom surveys both after dose 1 and after dose 2. We defined appreciable post-vaccine symptoms as those of at least moderate severity and lasting at least 2 days. We found that symptoms were more frequent following the second vaccine dose than the first (74% vs. 60%, P < 0.001), with >80% of all symptoms resolving within 2 days. The most common symptom was injection site pain, followed by fatigue and malaise. Overall, 20% of participants experienced appreciable symptoms after dose 1 and 30% after dose 2. In multivariable analyses, female sex was associated with greater odds of appreciable symptoms after both dose 1 (OR, 95% CI 1.73, 1.19-2.51) and dose 2 (1.76, 1.28-2.42). Prior COVID-19 was also associated with appreciable symptoms following dose 1, while younger age and history of hypertension were associated with appreciable symptoms after dose 2. We conclude that most post-vaccine symptoms are reportedly mild and last <2 days. Appreciable post-vaccine symptoms are associated with female sex, prior COVID-19, younger age, and hypertension. This information can aid clinicians in advising patients on the safety and expected symptomatology associated with vaccination